JAGUAR HEALTH, INC. Accrued Vacation, Current
JAGUAR HEALTH, INC. (JAGX) had Accrued Vacation, Current of $366.00 thousand as of 2026-06-30, per its 10-Q filed 2026-08-19.
Financial Statements › Notes › Accrued Liabilities, Current › Employee-related Liabilities, Current
us-gaap:AccruedVacationCurrent · last filed 2026-08-19
- 2026-06-30: Accrued Vacation, Current $366.00K.
- 2026-03-31: Accrued Vacation, Current $355.00K.
- 2025-12-31: Accrued Vacation, Current $357.00K.
- 2024-12-31: Accrued Vacation, Current $393.00K.
| Period end | Accrued Vacation, Current | Accrued Vacation, Current as first filed |
|---|---|---|
| 2026-06-30 | $366.00K 10-Q · filed 2026-08-19 | |
| 2026-03-31 | $355.00K 10-Q · filed 2026-05-20 | |
| 2025-12-31 | $357.00K 10-Q · filed 2026-08-19 | |
| 2024-12-31 | $393.00K 10-K · filed 2026-04-07 | |
| 2023-12-31 | $377.00K 10-K · filed 2025-03-31 | |
| 2022-12-31 | $310.00K 10-K · filed 2024-04-01 | |
| 2021-12-31 | $281.00K 10-K · filed 2023-03-24 | |
| 2020-12-31 | $277.00K 10-K · filed 2022-03-11 | |
| 2019-12-31 | $273.00K 10-K · filed 2021-03-31 | $272.82K 10-K · filed 2020-04-03 |
| 2018-12-31 | $287.33K 10-K · filed 2020-04-03 | |
| 2018-03-31 | $287.52K 10-Q · filed 2018-05-15 | |
| 2017-12-31 | $264.30K 10-K · filed 2019-04-10 | |
| 2017-09-30 | $264.22K 10-Q · filed 2017-11-20 | |
| 2017-06-30 | $231.72K 10-Q · filed 2017-08-09 | |
| 2017-03-31 | $229.94K 10-Q/A · filed 2017-06-23 | |
| 2016-12-31 | $223.77K 10-K · filed 2018-04-09 | |
| 2016-09-30 | $191.49K 10-Q · filed 2016-11-14 | |
| 2016-06-30 | $200.88K 10-Q · filed 2016-08-15 | |
| 2016-03-31 | $171.81K 10-Q · filed 2016-05-10 | |
| 2015-12-31 | $187.73K 10-K · filed 2017-02-15 | |
| 2015-09-30 | $173.47K 10-Q · filed 2015-11-13 | |
| 2015-06-30 | $185.71K 10-Q · filed 2015-08-13 | |
| 2015-03-31 | $146.28K 10-Q · filed 2015-06-26 | |
| 2014-12-31 | $140.41K 10-K · filed 2016-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Latigo Biotherapeutics, Inc. (LTGO) | United States | $1.176B | |
| LB PHARMACEUTICALS INC (LBRX) | United States | $1.220B | -10.87 |
| OPKO HEALTH, INC. (OPK) | United States | $1.220B | -15.59 |
| Seaport Therapeutics, Inc. (SPTX) | United States | $1.131B | |
| HARROW, INC. (HROW) | United States | $1.240B | -42.77 |
| Damora Therapeutics, Inc. (DMRA) | $1.250B | -6.10 | |
| Amphastar Pharmaceuticals, Inc. (AMPH) | United States | $1.116B | 10.93 |
| Avalyn Pharma Inc. (AVLN) | United States | $1.267B | |
| First Tracks Biotherapeutics, Inc. (TRAX) | United States | $1.280B | |
| Alto Neuroscience, Inc. (ANRO) | United States | $1.065B | -11.02 |